Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Clinical Trials Development & Member Site Core

加拿大癌症试验组 - 加拿大合作临床试验网络：临床试验开发

• 批准号: 10116970
• 负责人: Janet Ellen Dancey
• 金额: $ 59.54万
• 依托单位: QUEEN'S UNIVERSITY AT KINGSTON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-06 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10116970
• 关键词: Address; Adolescent; Adolescent and Young Adult; Adult; Advocacy; Awareness; Brain; Breast; Canada; Cancer Biology; Cell Therapy; Child; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Clinical Trials Unit; Collaborations; Collection; Communication; Communication Tools; Conduct Clinical Trials; Consent Forms; Continuing Education; Data Set; Development; Diagnosis; Education; Ensure; Ethics; Head and Neck Cancer; Health; Hematology; Human Resources; Image; Information Technology; Institutional Review Boards; International; Intervention; Joints; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Molecular; Monitor; Operative Surgical Procedures; Patients; Pharmacotherapy; Policies; Population; Process; Protocols documentation; Recommendation; Regulation; Research; Research Personnel; Role; Scientific Advances and Accomplishments; Site; Skin; Societies; Technology; Testing; Time; Translational Research; Translations; Work; cancer therapy; clinical development; data sharing; digital health; experience; improved; innovation; lifestyle intervention; member; method development; novel therapeutics; precision medicine; rare cancer; research clinical testing; technology development; tool; urologic; web portal; working group

Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental re- evaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN's scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada's largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.

总结 癌症生物学和技术的变革性进展，以分子水平表征癌症 水平，再加上新药和细胞疗法的迅速发展，要求从根本上重新 评估临床试验设计和交付，以确保最大的患者和社会效益。的 加拿大癌症试验集团（CCTG）与美国研究人员和团体建立了强有力的合作伙伴关系， NCTN强调国际合作，以进行明确实践改变试验，试验 在罕见的癌症环境中，以及测试精确医学策略的试验。加拿大合作 NCTN的临床试验网络（CCCTN），CCTG通过以下方式扩展了NCTN的科学专业知识：1） 让其网络中最优秀和最聪明的人参与NCTN的领导角色; 2）增加临床试验 通过包括加拿大所有中心在内的国家网络提高能力; 3） 加拿大患者，这对于在罕见人群中测试干预措施的试验尤为重要。CCTG 有助于科学概念的发展、收益、生物标本收集和网络领导， 在试验实施的工具部分（包括信息技术和 法规）。CCTG开发并参与NCTN成人癌症试验组合，包括乳腺癌、肺癌、 泌尿系统和胃肠道恶性肿瘤，在不常见/罕见的未满足需求的情况下，如 血液、皮肤、脑和头颈部癌症，包括服用AYA的青少年和年轻人 审判此外，CCTG利用机会扩大其试验活动范围，以包括手术 以及生活方式干预和成像和数字健康终点。研究包括翻译 科学和其他相关终点，以丰富来自NCTN试验和方法的信息， 技术开发，以改善临床试验设计、终点和执行。最后，CCTG 作为其数据共享政策的一部分，提供来自NCTN试验的试验数据集。作为CCCTN，CCTG， 加拿大最大和最有经验的临床试验单位，创造和提供创新的战略， 来自NCTN加速将科学进步转化为癌症的改善 治疗改善儿童，青少年和成年人诊断患有癌症的生活。